Take part in a paid clinical trial

The study drug is being developed as a new potential treatment for people living with amyotrophic lateral sclerosis (ALS), also known as motor neuron disease. ALS is a condition where nerve cells that control movement slowly stop working. In people with ALS, a protein called TDP‑43 builds up in clumps inside nerve cells, which is believed to damage them and make the disease worse.

The study drug is designed to break down these harmful protein clumps while leaving the normal protein alone. By doing this, the drug may help nerve cells work more normally and slow down damage over time.

This is a healthy volunteer study. Before a new treatment can be studied in people with ALS, it must first be carefully evaluated in healthy volunteers. This initial study helps researchers understand how the study drug behaves in the body, how it is processed, and whether it is safe and well tolerated. The information collected in healthy volunteers is an important step in supporting future studies in people living with ALS.

This clinical trial is sponsored by a pharmaceutical company. It is investigating a potential drug (the study drug) for inflammatory and fibrotic conditions. These include long-term digestive diseases such as ulcerative colitis and Crohn’s disease, where ongoing inflammation and scarring can damage the intestines. Some current treatments may not work for everyone and can cause significant side effects. This trial is designed to assess the safety and potential benefits of an investigational study drug that may offer an additional option for people who do not respond well to existing therapies. This trial is being held in Brisbane.

We’re currently looking for adults aged 18 to 65 who are experiencing androgenetic alopecia (AGA), also known as pattern hair loss, to take part in The Headline Trial.

Hair loss is common and can affect both men and women. This clinical study is investigating new approaches that may help shape future treatment options.

You don’t need a formal diagnosis to get started. If you think you may have AGA, you can begin with a quick pre-screen. This helps us assess whether you may meet the initial study requirements. Completing the pre-screen doesn’t guarantee enrolment, but it’s an important first step in seeing whether the study may be suitable for you.

By getting involved, you’ll be contributing to research that aims to improve future options for people affected by hair loss.

Overgrowth conditions are rare disorders where certain parts of the body grow more than they should. This happens because of a change in a gene called PIK3CA, which normally helps control how cells grow. In these conditions, the gene sends too many growth signals, causing extra tissue or abnormal blood vessels to form in specific areas, such as an arm, leg, or part of the body. The change isn’t inherited and only affects some cells, which is why the overgrowth is uneven rather than affecting the whole body. Over time, this extra growth can lead to pain, swelling, movement difficulties, or circulation issues, and may gradually worsen if left untreated. We are looking at a potential new oral treatment for these conditions, due to the limitations in current treatment.